Indaptus Therapeutics Shares Soar 125% After It Gets Notice Of Allowance From US Patent Office

Shares of Indaptus Therapeutics, Inc. (INDP) more than doubled on Wednesday morning after the pre-clinical stage biotech company received notice of allowance from the U.S. Patent and Trademark Office for a strategic patent.

INDP is currently trading at $15.85, up $8.78 or 124.25%, on the Nasdaq, on a volume of 35.7 million shares, far above average volume of 925 thousand shares. The stock has traded between $6.84 and $36.80 in the 52 week period.

Indaptus Therapeutics said it thePatent and Trademark Office issued a notice of allowance for claims related to the company's platform technology. The patent, titled, "Methods of Treatment of Infections Using Bacteria," provides broad protection for the application of the company's platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.

Indaptus Therapeutics develops a patented anti-cancer and antiviral immunotherapy. It engages in developing a pre-clinical pipeline of therapeutic candidates intended to elicit anti-tumor and anti-viral responses, as well as cure diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT